首頁 > 市場調查報告書 > 醫療設備

體外診斷

市場調查報告書

商品編碼

1623508

血液篩檢市場規模（按類型、技術、最終用戶、地區、範圍和預測）

Blood Screening Market Size by Type, By Technology (Nucleic Acid Testing, Enzyme-Linked Immunosorbent Assay, Rapid Tests, Western Blotting), By End User, By Geographic Scope and Forecast

出版日期: 2024年09月24日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

血液篩檢市場規模及預測

2023 年血液篩檢市場規模價值 27 億美元，預計到 2031 年將達到 54 億美元，預測期內（2024-2031 年）的複合年增長率為 8.6%。

血液篩檢是分析血液樣本以識別感染、疾病和失調的過程。識別愛滋病毒、肝炎等病毒和其他血液傳染，確保輸血安全並儘早發現以進行治療，為整體公共衛生和疾病預防工作做出貢獻。

血液篩檢可以檢測出愛滋病毒、肝炎和瘧疾等傳染病，從而實現安全輸血。它可以檢測糖尿病和高膽固醇等慢性疾病，幫助早期診斷癌症，監測器官功能，並透過檢測多種疾病的風險因素來促進預防保健，從而改善整體公共衛生和安全。

血液篩檢的未來應用將改善早期疾病識別，並為癌症和心血管疾病等疾病提供個人化的治療策略。先進技術正在提高識別基因標記和傳染病的準確性，從而實現更好的預防保健、慢性病監測以及更安全的輸血和器官移植。

血液篩檢市場動態

影響血液篩檢市場的關鍵市場動態

主要市場驅動因子

增加捐血量：

增加捐血量：全球捐血和輸血量的增加對有效的血液篩檢方法產生了需求。

傳染病發生率不斷上升：

愛滋病毒、肝炎和寨卡病毒等傳染病的發生率不斷上升，需要嚴格的血液篩檢規程。

技術進步：

核酸擴增檢驗（NAT）和次世代定序（NGS）等血液篩檢技術的創新正在提高血液檢測的準確性和效率。

政府措施：

政府的支持性政策和對血液安全計劃的資助正在推動市場成長。

民族意識：

大眾對血液安全重要性的認識不斷提高，促進了市場擴張。

主要問題：

篩檢成本高：

先進篩檢技術的高成本可能會成為其採用的障礙，尤其是在發展中國家。

監理的嚴格程度：

嚴格的監管要求和新篩選技術的冗長的審批流程可能會阻礙市場成長。

限制低收入地區的接取：

低收入地區有限的基礎設施和資源限制了先進血液篩檢方法的實施。

主要趨勢：

自動化血液篩檢：

將自動化融入血液篩檢過程可提高吞吐量並減少人工錯誤。

人工智慧的採用：

人工智慧和機器學習在血液篩檢的數據分析和解釋中的應用越來越多，從而提高了診斷的準確性。

即時檢定：

血液篩檢中即時診斷檢測 (POCT) 的興起提供了快速可靠的結果，尤其是在偏遠和服務不足的地區。

血液篩檢市場的區域分析

北美

根據經過驗證的市場研究，北美預計將主導血液篩檢市場。

這一優勢源於對輸血的高需求、先進的醫療保健基礎設施以及 Grifols、雅培實驗室和 Bio-Rad 實驗室等知名企業的存在。

此外，嚴格的監管框架和公眾對血液安全的認識也是北美在市場上佔據領先地位的因素。

亞太地區

根據 Verified Market Research 的調查，亞太地區是血液篩檢市場成長最快的地區。

預計亞太地區將見證血液篩檢市場的最高成長率。

醫療保健基礎設施的擴大、捐血量的增加以及傳染病患者病率的上升正在推動市場的成長。

中國、印度和日本等國家正致力於加強血液篩檢規程並採用先進技術。

Blood screening is the process of analysing blood samples to identify infections, illnesses and disorders. It identifies viruses such as HIV, hepatitis and other blood-borne infections, ensuring blood transfusion safety and early detection in medical treatments and thereby contributing to overall public health and disease prevention initiatives.

Blood screening detects infectious disorders such as HIV, hepatitis and malaria, allowing for safe blood transfusions. It detects chronic disorders like diabetes and high cholesterol, helps with early cancer diagnosis, monitors organ function, and promotes preventative healthcare by detecting risk factors for numerous illnesses, thereby improving general public health and safety.

Future applications of blood screening will improve early disease identification, allowing for individualized treatment strategies for ailments such as cancer and cardiovascular disease. Advanced technology will improve the accuracy with which genetic markers and infections are identified, allowing for better preventive care, chronic condition monitoring and safer blood transfusions and organ transplantations.

Blood Screening Market Dynamics

The key market dynamics that are shaping the Blood Screening Market include:

Key Market Drivers:

Increasing Blood Donations:

A growing number of blood donations and transfusions worldwide is driving the demand for efficient blood screening methods.

Rising Prevalence of Infectious Diseases:

The increasing incidence of infectious diseases such as HIV, hepatitis, and Zika virus necessitates rigorous blood screening protocols.

Technological Advancements:

Innovations in blood screening technologies, including nucleic acid amplification tests (NAT) and next-generation sequencing (NGS), are enhancing the accuracy and efficiency of blood tests.

Government Initiatives:

Supportive government policies and funding for blood safety programs are propelling the market growth.

Public Awareness:

Increased public awareness about the importance of blood safety is contributing to the market expansion.

Key Challenge:

High Costs of Screening:

The high cost of advanced screening technologies can be a barrier for adoption, especially in developing countries.

Regulatory Stringency:

Stringent regulatory requirements and lengthy approval processes for new screening technologies can hinder market growth.

Limited Access in Low-Income Regions:

Limited infrastructure and resources in low-income regions restrict the implementation of advanced blood screening methods.

Key Trends:

Automation in Blood Screening:

The integration of automation in blood screening processes is improving throughput and reducing manual errors.

Adoption of Artificial Intelligence:

AI and machine learning are being increasingly adopted for data analysis and interpretation in blood screening, enhancing diagnostic accuracy.

Point-of-Care Testing:

The rise of point-of-care testing (POCT) for blood screening is providing quick and reliable results, particularly in remote and underserved areas.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Blood Screening Market Regional Analysis

Here is a more detailed regional analysis of the blood screening market:

North America

According to Verified Market Research, North America is expected to dominate the blood screening market.

This dominance is driven by a high demand for blood transfusions, advanced healthcare infrastructure, and the presence of established players like Grifols, Abbott Laboratories, and Bio-Rad Laboratories.

Additionally, stringent regulatory frameworks and public awareness about blood safety contribute to North America's leading position in the market.

Asia Pacific

According to Verified Market Research, Asia Pacific is fastest growing region in blood screening market.

The Asia Pacific region is expected to witness the highest growth rate in the blood screening market.

The expanding healthcare infrastructure, increasing blood donations, and rising prevalence of infectious diseases are driving the market growth.

Countries like China, India, and Japan are focusing on enhancing their blood screening protocols and adopting advanced technologies.

Blood Screening Market Segmentation Analysis

The Blood Screening Market is segmented on the basis of Type, Application and Geography.

Blood Screening Market, By Type

Reagents & Kits
Instruments
Software & Services

Based on Type, the market is segmented into Reagents & Kits, Instruments and Software & Services. Reagents & kits accounted for the largest market share in the global blood screening market. The growing prevalence of infectious diseases and the rising need for safe blood transfusions have driven the demand for high-quality reagents and kits. These products are essential for detecting pathogens in donated blood, ensuring the safety and reliability of blood transfusions. As healthcare facilities and blood banks prioritize accuracy and efficiency in blood screening processes, the adoption of advanced reagents and kits is significantly increasing. This trend reflects the ongoing efforts to enhance blood safety and the overall quality of healthcare services.

Blood Screening Market, By Technology

Nucleic Acid Testing (NAT)
Enzyme-Linked Immunosorbent Assay (ELISA)
Rapid Tests
Western Blotting

Based on Technology, the market is segmented into Nucleic Acid Testing (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests and Western Blotting. In the Blood Screening Market, Nucleic Acid Testing (NAT) is the dominant technology. NAT is highly favored for its ability to detect viral genetic material at an early stage, significantly reducing the window period during which infections may not be detected by traditional serological methods. This technology ensures a higher level of safety and reliability in blood screening processes, making it crucial for preventing the transmission of infectious diseases through blood transfusions.

Blood Screening Market, By End User

Blood Banks
Hospitals
On the basis of End User, the market is divided into Blood banks and Hospitals. In the blood screening market, blood banks are the dominant end users. Blood banks play a critical role in ensuring the safety and availability of blood for transfusions. They employ rigorous blood screening protocols to detect infectious agents, thereby maintaining the highest standards of blood safety and mitigating the risk of transfusion-transmitted infections.

Blood Screening Market, By Geography

North America
Europe
Asia Pacific
Latin America
Middle East and Africa
On the basis of Geography, the Blood Screening Market is classified into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America accounted for the largest market share in the global blood screening market. The region's dominance is attributed to the well-established healthcare infrastructure, high healthcare expenditure, and the presence of key market players. Moreover, the increasing prevalence of chronic diseases and the rising number of surgical procedures requiring blood transfusions have further boosted the demand for blood screening in North America. The region's strong focus on blood safety, coupled with continuous advancements in screening technologies, ensures the growth and sustainability of the blood screening market.

Key Players

The "Blood Screening Market" study report will provide valuable insight with an emphasis on the global market, including some of the major players in the industry such as
Abbott Laboratories, Grifols, Bio-Rad Laboratories, Roche Diagnostics, Thermo Fisher Scientific, Siemens Healthineers, Ortho Clinical Diagnostics, Becton Dickinson.

Our market analysis offers detailed information on major players wherein our analysts provide insight into the financial statements of all the major players, product portfolio, product benchmarking and SWOT analysis. The competitive landscape section also includes market share analysis, key development strategies, recent developments, and market ranking analysis of the above-mentioned players globally.

Blood Screening Market Recent Developments
In March 2023, Abbott Laboratories introduced a new high-throughput screening system for detecting infectious diseases in donated blood.
In August 2023, Roche Diagnostics launched a next-generation sequencing platform for comprehensive blood screening.
In October 2023, Siemens Healthineers entered into a collaboration with a leading blood bank to implement advanced screening technologies.

1 INTRODUCTION OF GLOBAL BLOOD SCREENING MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL BLOOD SCREENING MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL BLOOD SCREENING MARKET, BY PRODUCT

5.1 Overview
5.2 Reagents & Kits
5.3 Instruments
5.4 Software & Services

6 GLOBAL BLOOD SCREENING MARKET, BY TECHNOLOGY

6.1 Overview
6.2 Nucleic Acid Amplification
6.3 ELISA
6.4 Rapid tests
6.5 NGS

7 GLOBAL BLOOD SCREENING MARKET, BY END USER

7.1 Overview
7.2 Blood Banks
7.3 Hospitals

8 GLOBAL BLOOD SCREENING MARKET, BY GEOGRAPHY

8.1 Overview
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.2.3 Mexico
8.3 Europe
- 8.3.1 Germany
- 8.3.2 U.K.
- 8.3.3 France
- 8.3.4 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Rest of Asia Pacific
8.5 Rest of the World
- 8.5.1 Latin America
- 8.5.2 Middle East & Africa

9 GLOBAL BLOOD SCREENING MARKET COMPETITIVE LANDSCAPE

9.1 Overview
9.2 Company Market Share
9.3 Vendor Landscape
9.4 Key Development Strategies

10 COMPANY PROFILES

10.1 Grifols
- 10.1.1 Overview
- 10.1.2 Financial Performance
- 10.1.3 Product Outlook
- 10.1.4 Key Developments
10.2 F. Hoffmann-La Roche
- 10.2.1 Overview
- 10.2.2 Financial Performance
- 10.2.3 Product Outlook
- 10.2.4 Key Developments
10.3 Abbott Laboratories
- 10.3.1 Overview
- 10.3.2 Financial Performance
- 10.3.3 Product Outlook
- 10.3.4 Key Developments
10.4 Biomerieux
- 10.4.1 Overview
- 10.4.2 Financial Performance
- 10.4.3 Product Outlook
- 10.4.4 Key Developments
10.5 Bio-Rad Laboratories, Inc.
- 10.5.1 Overview
- 10.5.2 Financial Performance
- 10.5.3 Product Outlook
- 10.5.4 Key Developments
10.6 Siemens Healthineers
- 10.6.1 Overview
- 10.6.2 Financial Performance
- 10.6.3 Product Outlook
- 10.6.4 Key Developments
10.7 Ortho Clinical Diagnostics, Inc.
- 10.7.1 Overview
- 10.7.2 Financial Performance
- 10.7.3 Product Outlook
- 10.7.4 Key Developments
10.8 Thermo Fisher Scientific, Inc.
- 10.8.1 Overview
- 10.8.2 Financial Performance
- 10.8.3 Product Outlook
- 10.8.4 Key Developments
10.9 Beckman Coulter
- 10.9.1 Overview
- 10.9.2 Financial Performance
- 10.9.3 Product Outlook
- 10.9.4 Key Developments
10.10 Becton, Dickinson and Company
- 10.10.1 Overview
- 10.10.2 Financial Performance
- 10.10.3 Product Outlook
- 10.10.4 Key Developments